Education
About Us
Working with TipRanks
Follow Us
eXoZymes (EXOZ)
NASDAQ:EXOZ
EXOZ Stock Chart & Stats
$11.49
--
Market closed
$11.49
--
Day’s Range― - ―
52-Week Range$7.08 - $18.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.40K
Market Cap
N/A
Enterprise Value$55.69M
Total Cash (Recent Filing)$5.10M
Total Debt (Recent Filing)$1.32M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Apr 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding8,387,250
10 Day Avg. Volume1,191
30 Day Avg. Volume2,398
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)12.87
Price to Sales (P/S)0.00
P/FCF Ratio-15.06
Enterprise Value/Market Cap10.00T>
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-197.52
Enterprise Value/Ebitda-6.83
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Production Scale-UpThe scale-up milestone demonstrates the scalability and efficiency of eXoZymes' platform, supporting potential commercial validation and leadership in sustainable biomanufacturing.
Balance Sheet HealthA manageable debt level and positive equity indicate financial flexibility and a solid foundation for future growth, despite current losses.
Industry LeadershipThe successful scale-up and collaboration with Cayman Chemical enhance eXoZymes' reputation and competitive position in the biomanufacturing industry.
Bears Say
Widening LossesThe widening losses reflect ongoing operational challenges and the absence of revenue, which may pressure financial resources and delay profitability.
Cash BurnSignificant cash burn indicates reliance on external funding, which could limit strategic options and increase financial risk if not addressed.
Pre-Revenue StatusThe lack of revenue generation underscores the company's early-stage status and the need for successful commercialization to achieve financial sustainability.
eXoZymes News
EXOZ FAQ
What was eXoZymes’s price range in the past 12 months?
eXoZymes lowest stock price was $7.08 and its highest was $18.40 in the past 12 months.
What is eXoZymes’s market cap?
Currently, no data Available
When is eXoZymes’s upcoming earnings report date?
eXoZymes’s upcoming earnings report date is Apr 08, 2026 which is in 33 days.
How were eXoZymes’s earnings last quarter?
eXoZymes released its earnings results on Nov 13, 2025. The company reported -$0.273 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.273.
Is eXoZymes overvalued?
According to Wall Street analysts eXoZymes’s price is currently Overvalued.
Does eXoZymes pay dividends?
eXoZymes does not currently pay dividends.
What is eXoZymes’s EPS estimate?
eXoZymes’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does eXoZymes have?
eXoZymes has 8,387,250 shares outstanding.
What happened to eXoZymes’s price movement after its last earnings report?
eXoZymes reported an EPS of -$0.273 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.606%.
Which hedge fund is a major shareholder of eXoZymes?
Currently, no hedge funds are holding shares in EXOZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
eXoZymes
eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.
EXOZ Earnings Call
Q3 2025
0:00 / 0:00
Technical Analysis
Ownership Overview
16.46% Insiders
0.49% Mutual Funds
― Other Institutional Investors
82.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---